NFATC2IP

Across TCGA pan-cancer cohorts, NFATC2IP mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of NFATC2IP’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where NFATC2IP mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types NFATC2IP is over-expressed in tumor.

CCRCC, COAD, and LSCC are the cancer types where NFATC2IP tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NFATC2IP mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.389	<.001	11	view →
COAD	Female	All	+0.323	<.001	8	view →
LSCC	Male	II,III,IV	+0.261	<.001	7	view →
LUAD	All	All	+0.115	<.001	6	view →
PDAC	All	All	+0.364	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

NFATC2IP–CCRCC

Open the CCRCC breakdown →